Latest Breaking News On - Jonathan silverberg - Page 6 : comparemela.com

Clinical Challenges: Is Recalcitrant Atopic Dermatitis Really Comorbid Disease?

Dupilumab failure signals the need for extended patch testing to identify a missed diagnosis

United statesJenny muraseJonathan silverbergKristin jenkinsAmerican contact dermatitis societyJournal of the american academy dermatologyUniversity of california san franciscoHealth sciencesGeorge washington university school of medicineAmerican academy of dermatologyAmerican academyGeorge washington university schoolCalifornia san franciscoMedpage todayReading roomAtopic dermatitis

Clinical Challenges: JAK Inhibitors for Atopic Dermatitis

Strong efficacy data for new class of agents in AD, but some apprehension over safety warnings

United statesNew havenNew yorkBrett kingAmys pallerLawrencef eichenfieldJonathan silverbergCameron rokhsarChris bunickKristin jenkinsYale school of medicineUniversity of california san diegoNorthwestern university feinberg school of medicineHealth sciencesGeorge washington university school of medicineCalifornia san diego

ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

27.10.2023 - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established eblasakimab’s potential to deliver a monthly .

United statesJonathan silverbergEmma thompsonAprilw armstrongAshleyr robinsonClinical research organizationSpurwing communicationsCompany annual report on formExchange commissionHealthy sciencesLifesci advisorsPharmaceuticals nasdaqStockholders of the companyDrug administrationCompany us securitiesWorld congress

2023-10-24 | NDAQ:ASLN | Press Release | Aslan Pharmaceuticals Ltd

(2023-10-24 | NDAQ:ASLN) ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

United statesAlex kaoukhovAshleyr robinsonJonathan silverbergAprilw armstrongEblasakimab closecurlyquoteDupilumab closecurlyquoteEmma thompsonExchange commission onPharmaceuticals nasdaqClinical research organizationLifesci advisorsSpurwing communicationsCompany closecurlydoublequoteEuropean academy of dermatologyGeorge washington university school of medicine

Rinvoq exhibits acceptable benefit and risk profile for AD treatment up to 140 weeks

Rinvoq exhibits acceptable benefit and risk profile for AD treatment up to 140 weeks
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Jonathan silverbergKristen dowdBygabrielle capaldoGeorge washington university school of medicineEuropean academy of dermatologyHealth scienceEuropean academyGeorge washington university school